Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients

Table 3 Outcomes of antiviral therapy in cirrhotic patients with spleen operation plus interferon treatment

Ref.	SVR rate	SVR rate (GT)	IFN dosage reduction	Discontinuation of therapy	Reasons of discontinuation therapy	HCC
Aizawa et al[17], 2013	6/30	GT 1: 3/25	12/30	41/1202	HCC occurrence 10; No VR 10; Fatigue 5; Thrombocytopenia 3; Fundal hemorrhage 2; Interstitial pneumonia 2; Anemia, auditory disturbance, pruritus, depression, presyncope, liver function flare, infection and death of accident 1,respectively	112
		GT 2/3: 3/5
Akahoshi et al[18], 2012	36/971	GT 1: 19/80	NA	8/97	Depression 3; Neutropenia 2; Appearance of HCC 2; Pneumococcal meningitis 1	2
		GT 2/3: 17/20
Hayashi et al[11], 2006	2/6	GT 1: 1/3	0/6	0/6	NO	NA
		GT 2/3: 1/2
Ikezawa et al[19], 2010	5/10	GT 1: 4/9	2/10	1/10	Angina 1	NA
		GT 2/3: 1/1
Ji et al[20], 2013	8/13	GT 1: 4/9	1/13	0/13	NO	NA
		GT 2/3: 4/4
Kedia et al[21], 2012	4/6	GT 1: 1/1	0/6	0/6	NO	NA
		GT 2/3: 3/4
Kercher et al[22], 2004	3/11	NA	8/11	0/11	NO	NA
Liang et al[23], 2008	3/9	GT 1: 1/4	0/9	2/9	Neutropenia 1; Anemia 1	NA
		GT 2/3: 2/5
Morihara et al[24], 2009	4/16	GT 1: 0/7	0/16	3/16	Severe thrombocytopenia 1; NSAID-induced liver injury 1; peripheral neuropathy 1	4
		GT 2/3: 4/4
Motomura et al[25], 2012	16/37	NA	NA	NA	NA	NA
Shigekawa et al[26], 2011	9/29	GT 1: 3/21	NA	11/29	HCC 9; Neutropenia 1; Peritonitis 1	9
		GT 2/3: 6/8
Xie et al[27], 2012	30/49	GT 1: 30/49	NA	1/49	Hypothyroidism 1	NA
Foruny et al[28], 2005	3/8	GT 1: 2/7	0/8	2/8	Intolerance (with no evidence of hematological toxicity) 1; Neutropenia 1	NA
		GT 2/3: 1/1
Miyake et al[29], 2008	6/10	GT 1: 2/6	3/10	2/10	Hepatic coma 1; Plural effusion 1	NA
		GT 2/3: 4/4
Tahara et al[30], 2011	9/30	GT 1: 1/15	16/30	4/30	Neutropenia2; Severe fatigue 2	4
		GT 2/3: 8/15
Takahara et al[31], 2011	3/11	GT 1: 2/10	5/11	1/11	Hepatic coma 1	NA
		GT 2/3: 1/1
Summary	147/3723	GT 1: 73/246	47/160	35/3054		19/1604
		GT 2/3: 55/74

¹Among a total of 100 patients, three did not start IFN therapy because of no recovery of platelet counts (2) and the appearance of HCC before IFN therapy (1);

²Not classified on the basis of spleen operation or no spleen operation;

³Among the 372 subjects who underwent spleen operation followed by anti-HCV therapy, 11 were still receiving treatment when the paper was drafted;

⁴Excluding Aizawa et al (2013) because no classification on the basis of spleen operation or no spleen operation. SVR: Sustained virological response; GT: Genotype; IFN: Interferon; HCC: Hepatocellular carcinoma; NA: Not available.